Who Paid My Doc
Brian Leyland Jones
Medical Oncology Sioux Falls, SD Medical Doctor
NPI 1174686547 CMS profile 98901
1000 E 23Rd St, Suite 200, Sioux Falls, SD 57105
General payments
$442,498
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$168,962
Through program year 2023, Brian Leyland Jones of Sioux Falls, SD is reported in the CMS Open Payments database as having received $442,498 across 365 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $168,962 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $37,829 | 30 | |
| 2022 | General | $61,648 | 53 | |
| 2021 | General | $64,591 | 49 | |
| 2020 | General | $41,307 | 36 | |
| 2019 | General | $237,124 | 197 |
Beside peers
- Brian Leyland Jones
- Medical Oncology median
- Middle half of Medical Oncology
- National median
In program year 2025, general payments to Brian Leyland Jones were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.
Show as a table
| Year | Brian Leyland Jones | Medical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $237,124 | $968 | $140–$6,658 | $163 |
| 2020 | $41,307 | $747 | $102–$5,891 | $114 |
| 2021 | $64,591 | $430 | $50–$4,098 | $132 |
| 2022 | $61,648 | $812 | $127–$4,907 | $149 |
| 2023 | $37,829 | $957 | $144–$5,248 | $160 |
| 2024 | $0 | $1,042 | $149–$5,650 | $164 |
| 2025 | $0 | $1,128 | $147–$5,675 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
365 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Medical Oncology in South Dakota
Practitioners in the same specialty and state, ranked by reported value.
All Medical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in South Dakota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.